Related Experiment Video
Updated: Sep 27, 2026

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
Published on: August 4, 2022
Immunomodulatory therapy for anterior segment ocular inflammation
1Institute of Ophthalmology and Visual Sciences, University of Medicine and Dentistry of New Jersey, Newark 07103, USA.
Purpose Of Review:
To outline immunomodulatory therapy for ocular inflammatory diseases of the anterior segment and to review the current literature regarding their efficacy and safety.
Recent Findings:
Most current studies concern immunomodulatory treatment of patients who have chronic, debilitating disease resistant to corticosteroids. The authors evaluated the efficacy of treatment, the side effect profiles and the potential for long-term remission.
Summary:
Immunomodulatory drugs are increasingly being used in ocular inflammatory disease to avoid the effects of chronic steroid therapy and to induce remission in patients with chronic disease. These therapies have shown efficacy in treating otherwise resistant disease with relative safety insofar as side effects are generally reversible and medications can be substituted if intolerable side effects arise. Future trends in treatment will emphasize more specific target molecules, less immunosuppressive drugs and modification of the immune environment to increase the rates of long-term remission.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Microbiome of the Eye
Ophthalmic Drug Delivery Systems